Healthcare
Darwin AG acquires 3% stake in genEplanet to enhance position in the biotechnology market
Back to overview
The project at a glance
Key Facts
Client
Novogenia
Acquiror
Darwin AG
Target
genEplanet osebna genetika, d.o.o.
Sellers
genEplanet, osebna genetika, d.o.o.
Healthcare
Vertical
Mid Cap
Deal Size in EUR
Slowenia, Austria, Germany
Countries
'%20stroke='%238B7E68'/%3e%3cline%20id='Line%2018'%20x1='10.1035'%20y1='0.5'%20x2='10.1035'%20y2='8.6029'%20stroke='%238B7E68'/%3e%3crect%20id='Rectangle%201946'%20x='0.5'%20y='3.74561'%20width='39'%20height='35.237'%20rx='3.5'%20stroke='%238B7E68'/%3e%3cline%20id='Line%2019'%20x1='30.4219'%20y1='0.5'%20x2='30.4219'%20y2='8.6029'%20stroke='%238B7E68'/%3e%3c/g%3e%3c/svg%3e)
2023
Year
“genEplanet’s portfolio perfectly complements Darwin’s investments and enables further development of personalized products. We wish both companies a successful future!”
Mark Walther
Managing Partner, Walther Transaction
Approach
Darwin is one of the leading biotechnology companies in Europe and active in the field of preventive and lifestyle genetic testing. Darwin AG aimed to invest in complementary areas such as laboratory services, personalized nutritional supplements and cosmetics.
Challenges
Secure the client’s strategic objective, including several discussions about strategic priorities. Find relevant targets in four areas via an extensive origination and qualification effort.
Results
Identification and qualification of about 150 potentially suited targets in Europe Ensuring access to the most suitable targets Two transactions for Darwin AG
